

1 ***Toxoplasma gondii* co-opts the unfolded protein response to enhance**
2 **migration and dissemination of infected host cells**

3
4 Leonardo Augusto^{a,b}, Jennifer Martynowicz^c, Parth H. Amin^a, Nada S. Alakhras^a, Mark H.
5 Kaplan^c, Ronald C. Wek^{a*}, William J. Sullivan, Jr^{b,c*}

6
7 ^aDepartment of Biochemistry & Molecular Biology, Indiana University School of Medicine,
8 Indianapolis, Indiana, 46202.

9 ^bDepartment of Pharmacology & Toxicology, Indiana University School of Medicine,
10 Indianapolis, Indiana, 46202.

11 ^cDepartment of Microbiology & Immunology, Indiana University School of Medicine,
12 Indianapolis, Indiana, 46202.

13
14 **Running title:** *Toxoplasma* infection induces host UPR and migration

15 *Corresponding authors:

16 Ronald C. Wek
17 Showalter Professor
18 Indiana University School of Medicine
19 635 Barnhill Drive
20 MS 4067A
21 Indianapolis, IN 46202
22 (317) 274-0549; rwek@iu.edu

16 William J. Sullivan, Jr.
17 Showalter Professor
18 Indiana University School of Medicine
19 635 Barnhill Drive
20 MS A418C
21 Indianapolis, IN 46202
22 (317) 274-1573; wjsulliv@iu.edu

26 **Abstract**

27 *Toxoplasma gondii* is an intracellular parasite that reconfigures its host cell to promote
28 pathogenesis. One consequence of *Toxoplasma* parasitism is increased migratory activity of host
29 cells, which facilitates dissemination. Here we show that *Toxoplasma* triggers the unfolded
30 protein response (UPR) in host cells through calcium release from the endoplasmic reticulum
31 (ER). We further found that host IRE1, an ER stress sensor protein activated during *Toxoplasma*
32 infection, also plays a noncanonical role in actin remodeling by binding filamin A in infected
33 cells. By inducing cytoskeletal remodeling via IRE1 oligomerization in host cells, *Toxoplasma*
34 enhances host cell migration *in vitro* and dissemination of the parasite to host organs *in vivo*. Our
35 study identifies novel mechanisms used by *Toxoplasma* to induce dissemination of infected cells,
36 providing new insights into strategies for treatment of toxoplasmosis.

37

38 **Keywords:** *Toxoplasma*, parasites, UPR, IRE1, PERK, cell migration, filamin A, host-pathogen
39 interactions

40 **Importance**

41 Cells that are infected with the parasite *Toxoplasma gondii* exhibit heightened migratory
42 activity, which facilitates dissemination of the infection throughout the body. In this study, we
43 identify a new mechanism used by *Toxoplasma* to hijack its host cell and increase its mobility.
44 We further show that the ability of *Toxoplasma* to increase host cell migration does not involve
45 the enzymatic activity of IRE1, but rather IRE1 engagement with actin cytoskeletal remodeling.
46 Depletion of IRE1 from infected host cells reduces their migration in vitro and significantly
47 hinders dissemination of *Toxoplasma* in vivo. Our findings reveal a new mechanism underlying
48 host-pathogen interactions, demonstrating how host cells are co-opted to spread a persistent
49 infection around the body.

50

51 **Introduction**

52 *Toxoplasma gondii* is an obligate intracellular parasite capable of infecting any nucleated
53 cell in warm-blooded vertebrates. Recent studies have revealed a striking degree of host cell
54 remodeling taking place in *Toxoplasma*-infected cells that serves to facilitate pathogenesis and
55 transmission. In addition to secreted parasite effectors that modulate host cell gene expression,
56 *Toxoplasma* infection can alter immune responses and enable dissemination to other host tissues
57 [1]. Therein, *Toxoplasma* can differentiate from the replicative tachyzoites to the latent
58 bradyzoite stage, enabling formation of tissue cysts that persist for the lifetime of the infected
59 host [2].

60 Upon host cell invasion, *Toxoplasma* forms a parasitophorous vacuole (PV) that serves as
61 a protective niche that can interface with the host cell cytoplasm to sequester nutrients [3].
62 Curiously, *Toxoplasma* recruits the host endoplasmic reticulum (ER) to the PV via association
63 between their respective membranes, although the reasons for this high affinity interaction are
64 not yet understood [4, 5].

65 The ER is sensitive to the perturbations in protein homeostasis through a stress-sensing
66 pathway known as the unfolded protein response (UPR). Three ER transmembrane proteins,
67 IRE1, ATF6, and PERK operate as sensors that activate the UPR, leading to changes in gene
68 expression that restore and expand the processing capacity of the organelle [6-8]. IRE1 (ERN1)
69 is a protein kinase and endoribonuclease that facilitates cytosolic splicing of *XBPI* (*XBPI*s)
70 mRNA, thereby enhancing expression of the *XBPI*s isoform, which induces transcription of
71 genes involved in ER-associated protein degradation (ERAD), lipid synthesis, and protein
72 folding [7, 8]. In response to ER stress, ATF6 transits from the ER to the Golgi apparatus where
73 it is cleaved, releasing an N-terminal cytosolic fragment (ATF6-N) that enters the nucleus and

74 activates UPR-target genes involved in protein folding and transport [6, 9]. PERK (EIF2AK3) is
75 the third UPR sensor, which phosphorylates eIF2 α to direct translational and transcriptional
76 modes of gene expression that regulate ER processing of proteins, metabolism, and the oxidation
77 status of cells [6, 10]. While the three ER stress sensory proteins function in parallel, there is
78 cross-regulation that serves to coordinate the timing and magnitude of the UPR. For example,
79 PERK was reported to induce expression of RPAP2, which serves to dephosphorylate and
80 repress IRE1, thereby providing a means for the cell to abort failed ER-stress adaptation and
81 trigger apoptosis [11].

82 In addition to its role in the UPR, IRE1 was recently shown to modulate cytoskeletal
83 remodeling and cell migration through direct interactions with the actin crosslinking factor
84 filamin A [12]. The role of IRE1 in cytoskeletal remodeling is enhanced by pharmacological
85 induction of ER stress, but occurs independent of IRE1 protein kinase and endoribonuclease
86 activities [12]; rather, IRE1 serves as a scaffolding protein for filamin A to orchestrate changes
87 in cellular motility. This is noteworthy because *Toxoplasma* stimulates host cell migration,
88 turning its host cell into a “Trojan Horse” that can ferry parasites throughout the body [13].
89 Given the recruitment of host ER to the PV, we postulated that migratory activities mediated by
90 IRE1 function in parasite dissemination. In the present study, we uncover a new mechanism by
91 which *Toxoplasma* alters host ER homeostasis to produce hypermigratory activity in infected
92 host cells. We show that during the course of *Toxoplasma* infection, the three UPR sensory
93 proteins in the host cells are activated by a process involving calcium release from the ER,
94 leading to IRE1 oligomerization, association with filamin A, and enhanced cell migration.
95 Importantly, the IRE1-associated migration is a crucial determinant for successful dissemination
96 of toxoplasmosis in a mouse model of infection.

97 **Results**

98 **Induction of the UPR in *Toxoplasma*-infected host cells**

99 It is currently unclear why intracellular tachyzoites recruit host ER to the parasite PV. To
100 address whether *Toxoplasma* perturbs host ER homeostasis, we infected mouse embryonic
101 fibroblast (MEF) cells with RH strain parasites and measured three primary markers of the host
102 UPR over a 36-hour time course. Within 12 h of infection, *Toxoplasma* increased activation of
103 PERK as measured by its self-phosphorylation (PERK-P), induced expression of ATF6 and
104 formation of its cleavage product ATF6-N, and increased levels of the IRE1-derived spliced
105 variant of XBP1 (XBP1s) (**Fig. 1A**). It is noteworthy that whereas expression of ATF6-N and
106 XBP1s were transient, with increased amounts of the proteins appearing between 12 to 20 h post-
107 infection (hpi), PERK-P increased throughout the 36 h of infection (**Fig. 1A**). These results
108 indicate that *Toxoplasma* infection causes ER stress that activates each of the sensory proteins of
109 the UPR with some differences in the duration of their induction.

110 Activation of IRE1 involves oligomerization that can be visualized by a pattern of
111 punctate spots by IFA [14-16]. We expressed EGFP-tagged IRE1 in MEF cells that were deleted
112 for the endogenous *IRE1* gene by CRISPR/Cas9 genome editing (**Fig. S1A-C**); upon
113 *Toxoplasma* infection, we observed formation of IRE1 foci that is consistent with reported IRE1
114 activation by oligomerization (**Fig. 1B**) [15, 16]. Furthermore, expression of *XBP1s* mRNA, and
115 its downstream target genes involved in ERAD and protein folding, were induced upon
116 *Toxoplasma* infection of wild-type (WT) MEF cells (**Fig. 1C**). These results indicate that IRE1
117 activation and signaling occur in response to *Toxoplasma* infection.

118 To further study the timing of UPR induction and potential cross-regulation between the
119 UPR sensors in infected cells, we measured *XBP1s* mRNA levels by RT-qPCR in WT, *IRE1*^{-/-},

120 or *PERK*^{-/-} MEF cells. In WT cells, levels of *XBPIs* mRNA rose sharply until 18 hpi (**Fig. 1D**),
121 consistent with the increase in *XBPIs* protein (**Fig. 1A**). As expected, *XBPIs* mRNA was not
122 detected in infected *IRE1*^{-/-} cells (**Fig. 1D**). By comparison, there was induced *XBPIs* mRNA
123 that was sustained during 36 h of *Toxoplasma* infection in *PERK*^{-/-} cells, indicating that without
124 PERK, IRE1 continues to facilitate *XBPIs* expression (**Fig. 1D**). These results are consistent
125 with the idea that PERK governs IRE1 activity as previously reported [11] and suggests that in
126 infected WT cells, PERK operates to attenuate the response of IRE1 after 18 hpi.

127

128 **IRE1 affects calcium release from ER in *Toxoplasma*-infected cells.**

129 Protein folding in the ER is highly sensitive to the concentration of calcium, which is
130 released from the organelle by ryanodine receptors (RyR) and inositol 1,4,5-triphosphate (IP₃)-
131 receptors (IP₃R) [17]. The ER is a major reservoir of calcium; disruptions of calcium
132 homeostasis can lead to unfolded proteins and initiation of the UPR [17]. To determine whether
133 calcium content is altered in the host ER during *Toxoplasma* infection, we first measured
134 cytosolic calcium in infected MEF cells. Over an 18-hour period, *Toxoplasma* infection induced
135 a steady increase in host cell cytosolic calcium levels (**Fig. 2A, Fig. S2A**). Basal calcium levels
136 in the cytosol of *IRE1*^{-/-} cells were lower compared to WT cells, as previously reported [18], with
137 some increase upon parasite infection (**Fig. 2A, Fig. S2A**). To assess the mode of calcium
138 release from the host ER during infection, we monitored calcium transport using Fluo-4AM in
139 the presence of antagonists of RyR or IP₃R. The cytosolic calcium levels were lower in infected
140 cells treated with either antagonist, with the most robust calcium reduction occurring with
141 inhibition of IP₃R (**Fig. 2B**). We further addressed the contribution of RyR and IP₃R to calcium
142 release by adding increasing doses of caffeine and IP₃, agonists of RyR and IP₃R receptor

143 activity [19], respectively, to WT and *IRE1*^{-/-} cells infected with *Toxoplasma* for 18 h and
144 incubated with Mag-Fluo-4. To compare calcium release between RyR and IP₃R in WT and
145 *IRE1*^{-/-} cells, the fluorescence values were represented as the percentage of calcium release and
146 the respective start points were normalized to untreated WT and *IRE1*^{-/-} cells, respectively. The
147 RyR agonist enhanced calcium to similar levels in infected WT or *IRE1*^{-/-} cells (**Fig. 2C**). By
148 comparison, the agonist IP₃ induced appreciable calcium release only in infected WT cells (**Fig.**
149 **2D**), indicating a role for IRE1 in regulating IP₃R activity as previous reported [18].
150 Surprisingly, the percentage of calcium release was higher when IP₃R was stimulated compared
151 to RyR, demonstrating that *Toxoplasma* infection differentially alters RyR and IP₃R activities.
152 Collectively, these results suggest that *Toxoplasma* infection induces significant calcium release
153 from the host ER by processes involving both IP₃R and RyR; this calcium release is influenced
154 by IRE1 and is a likely contributor to the activation of the host ER-stress sensor proteins seen in
155 Figure 1A.

156

157 **IRE1 activation induces cell migration in infected cells**

158 *Toxoplasma* triggers rapid morphological changes in host cells, including disappearance
159 of podosome structures and appearance of lamellipodia [20]. IRE1 has recently been shown to
160 have noncanonical functions in actin cytoskeletal remodeling by directly binding to filamin A
161 [12]. To address whether activation of IRE1 by *Toxoplasma* infection enhances host cell
162 migration, we quantified the number of lamellipodia per infected cell normalized to uninfected
163 cells (**Fig. 3A, Fig. S3A**). At 18 hpi, *Toxoplasma* infection increased the number of lamellipodia
164 in WT cells and these structures were significantly diminished in IRE1-deficient cells (**Fig. 3A**).
165 By comparison, there were greater numbers of lamellipodia in PERK-deficient cells or those

166 treated with a PERK inhibitor, consistent with the idea that PERK is a negative regulator of IRE1
167 (**Fig. 3A**). Of interest, treatment with inhibitors of IRE1, namely 4 μ 8c, which interferes with
168 endoribonuclease activity, and KIRA6, which blocks IRE1 protein kinase activity, did not
169 change the number of lamellipodia compared infected cells treated with vehicle (**Fig. 3A**). These
170 results indicate that IRE1 can control migration of *Toxoplasma* infected cells independent of its
171 known enzymatic activities.

172 The functions of filamin A in cytoskeleton dynamics and cell migration is dependent on
173 phosphorylation of serine 2,152 (S2152) [21]. We detected a sharp increase in filamin A
174 phosphorylation in MEF cells infected with *Toxoplasma* for 18 h, which was not observed in
175 host cells lacking IRE1 (**Fig. 3B**). To address whether there is an association between IRE1 and
176 filamin A, we expressed myc-tagged filamin A (myc-FLNA) in WT MEF cells. Following 18 h
177 of *Toxoplasma* infection, we then performed an immunoprecipitation (IP) of the tagged filamin
178 A, followed by immunoblot measurements of associated IRE1. There was enhanced association
179 of IRE1 with filamin A in cells infected with the parasite compared to those uninfected (**Fig.**
180 **3C**).

181 Next, we measured changes in host cell transmigration upon parasite infection and
182 determined that there was a 2-fold increase in migration of WT MEF cells upon infection with
183 *Toxoplasma* (**Fig. 3D, Fig. S3B**). Increased host cell migration was observed regardless of
184 whether the cells were infected with type I RH or type II ME49 strain parasites (**Fig. S3C**). In
185 contrast, parasite infection did not induce migration of cells lacking IRE1. Levels of migration in
186 infected WT MEF cells treated with the IRE1 enzymatic inhibitors, KIRA6 or 4 μ 8c, or an ATF6
187 inhibitor (Ceapin-A7), were not significantly changed compared to untreated infected MEF cells,
188 nor were they altered in cells lacking the downstream IRE1 target XBP1 (**Fig. 3D**). Notably,

189 *Toxoplasma*-induced migration of PERK-deficient cells or WT treated with PERK inhibitor was
190 increased >2.5-fold upon parasite infection compared to infected cells with functional PERK
191 (**Fig. 3D**). These results suggest that IRE1 plays a critical role in inducing migration of
192 *Toxoplasma*-infected cells and that this migration is independent of the protein kinase and
193 endoribonuclease activities of IRE1 and its downstream target *XBPI*. Furthermore, PERK is
194 suggested to dampen both IRE1 functions in *XBPI* mRNA splicing and cell migration, which are
195 induced upon *Toxoplasma* infection.

196

197 **ER stress induces cell migration by mechanisms involving IRE1 oligomerization**

198 To better understand the mechanisms by which IRE1 enhances host cell migration in
199 response to *Toxoplasma* infection, we rescued the *IRE1*^{-/-} cells by expressing WT or defined
200 mutant versions of IRE1 (**Fig. 3E**). Equal amounts of the IRE1 proteins were expressed as
201 judged by immunoblot and immunofluorescence analyses (**Fig. S4A and B**). As expected, *ire1*-
202 *wt* rescued the migration capacity of infected cells (**Fig. 3E**). Expression of IRE1 defective in
203 kinase (*ire1-kD*) or endoribonuclease (*ire1-eD*) activities still rescued the migration phenotype,
204 further supporting the idea that these activities are dispensable for induced cell migration in
205 response to parasite infection (**Fig. 3E**). In contrast, cells expressing IRE1 with mutations in the
206 oligomerization domain (*ire1-oD*) were deficient in *Toxoplasma*-induced migration (**Fig. 3E**).
207 Furthermore, a truncated c-terminal version of IRE1 (*ire1-Δ965*) lacking the proline-rich
208 carboxy-terminal segment of IRE1 that binds filamin A [12] was also impaired in cell migration
209 following infection (**Fig. 3E**). As anticipated, only *ire1-wt* and *ire1-Δ965* showed induction of
210 spliced *XBPI* mRNA upon pharmacological induction of ER stress (**Fig. S4C**). These results
211 suggest that *Toxoplasma* infection induces IRE1 oligomerization (see also Fig. 1B), and that the

212 hypermigratory behavior of infected host cells is reliant on both the oligomerization domain and
213 the portion of IRE1 that interacts with filamin A.

214 Since we found that *Toxoplasma* induces calcium release from the host ER upon
215 infection, we examined the importance of calcium release in host cell migration induced by
216 *Toxoplasma*. We treated infected cells with RyR and IP₃R receptor blockers or activators during
217 the migration assay: ryanodine (Ry) or xestospongine-C (XeC) were used to inhibit RyR and IP₃R
218 receptors, respectively; caffeine or IP₃ were used to activate RyR and IP₃R receptors,
219 respectively. When infected cells were treated with the RyR and IP₃R activators (releasing
220 calcium from ER into the cytosol), the migration levels increased compared to cells not treated
221 with these agents. By contrast, addition of the IP₃R inhibitor significantly decreased migration of
222 the infected cells (**Fig. 3F**), consistent with IP₃R being the major calcium release receptor
223 involved in triggering the host UPR following *Toxoplasma* infection (**Fig. 2B**). These results
224 support the idea that calcium release from the host ER contributes to IRE1 activation and its
225 subsequent role in augmenting migration in response to infection.

226

227 **IRE1 controls host cell migration in infected immune cells *in vitro*.**

228 *Toxoplasma* makes use of immune cells as a “Trojan Horse” to disseminate to distal
229 organs and tissues throughout the body of the infected host [13]. To address whether *Toxoplasma*
230 is targeting IRE1 in immune cells to enhance their migration and facilitate dissemination, we
231 infected bone marrow-derived dendritic cells (DCs) with *Toxoplasma*. Levels of *XBPIs* mRNA
232 were sharply increased upon *Toxoplasma* infection in DCs (**Fig. 4A**), consistent with the idea
233 that the parasite infection activated IRE1 in this cell type. Next, we used CRISPR/Cas9 and two
234 distinct sgRNAs (sgRNA 1 and 2) to disrupt IRE1 in DCs (**Fig. S5A**). The sgRNA1 and sgRNA2

235 decreased *IRE1* mRNA levels by 66% and 93%, respectively (**Fig. 4B**). Each gRNA also led to a
236 corresponding reduction in IRE1 protein in DCs, with sgRNA2 leading to no detectable IRE1
237 (**Fig. 4C**). IRE1-depleted DCs (*ire1* (-)) did not exhibit decreased cell viability compared to WT,
238 nor did they show any difference in infectivity with *Toxoplasma* (**Fig. 4D, Fig. S5B**). However,
239 loss of IRE1 in DCs significantly lowered the transmigratory capacity following infection with
240 either Type I or Type II strains of *Toxoplasma* (**Fig. 4E, Fig. S3D**). To determine whether IP₃R
241 plays a role in the migration of infected DCs, we carried out the migration assay in the presence
242 of XeC. Inhibition of IP₃R resulted in a loss of host cell migration following 18 h of *Toxoplasma*
243 infection (**Fig. 4F**), further supporting the importance of calcium homeostasis in the ER for
244 migration of *Toxoplasma* infected cells. To test whether IRE1 controls the migration of infected
245 macrophages as well, we used CRISPR/Cas9 to deplete IRE1 in J774.1 macrophages (**Fig. 4G**
246 **and H**). As observed for DCs, the loss of IRE1 significantly reduced the ability of infected
247 macrophages to migrate (**Fig. 4I**).

248

249 **IRE1 facilitates dissemination of *Toxoplasma* in vivo**

250 To determine the importance of IRE1 in the migration of infected DCs *in vivo*, we
251 inoculated C57BL/6 mice intraperitoneally (i.p.) with infected WT or infected *ire1* (-) DCs and
252 measured parasite burden in the spleen by PCR at the designated time intervals over 3 days.
253 Depletion of IRE1 in the DCs by CRISPR/Cas9 was confirmed by RT-qPCR and immunoblot
254 analyses (**Fig. 5A and B**). Moreover, we ascertained that there was no significant difference in
255 parasite infection of WT and IRE1-depleted DCs (**Fig. 5C**). *Toxoplasma* was first detected in the
256 spleens of mice 12 h following i.p. inoculation with infected WT DCs, increasing at each time
257 point over the 3-day period (**Fig. 5D**). In striking contrast, appreciable levels of *Toxoplasma*

258 dissemination of infected IRE1-depleted DCs to the spleen were not detected until 3 days
259 following inoculation of the mice (**Fig. 5D**). Even at the 3-day time point, the loss of IRE1 from
260 DCs produced lowered levels of parasitemia in the spleen that were similar to those measured at
261 12 h of infected WT DCs. We also measured the *Toxoplasma* dissemination to the brain at 3
262 days, finding 200-fold fewer parasites when infected IRE1-depleted DCs were inoculated into
263 the mice (**Fig. 5E**). Mice inoculated with infected DCs lacking IRE1 survived significantly
264 longer than mice receiving infected WT DCs (**Fig. 5F**). These results demonstrate a novel role
265 for host IRE1 in parasite pathogenesis, as IRE1 is crucial for the migration of immune cells
266 being co-opted as “Trojan Horses” for parasite dissemination.

267

268 **Discussion**

269 Obligate intracellular pathogens create a niche inside of their host cell that allows for
270 parasite protection, nutrient acquisition, and the controlled release of pathogen effectors that
271 promote infection and dissemination. *Toxoplasma* tachyzoites reside inside of a nonfusogenic
272 parasitophorous vacuole (PV) that forms intimate contacts with host organelles and vesicles,
273 including the ER and mitochondria [4, 5]. It is suggested that the recruitment of host organelles
274 to the PV allows *Toxoplasma* to control critical host cell operations, including antigen
275 presentation, nutrient production, and suppression of apoptosis [5]. In this study, we addressed
276 consequences of the *Toxoplasma*-ER engagement on parasite infection and dissemination in the
277 host. As illustrated in a model presented in **Fig. 5G**, we showed that *Toxoplasma* infection
278 activates each of the UPR sensor proteins, including IRE1, via ER stress that results at least in
279 part from release of calcium from the organelle, primarily through IP₃R. In addition to its role in
280 the UPR, IRE1 has recently been shown to have noncanonical functions associated with the

281 remodeling of the cytoskeleton through direct interactions with the actin crosslinking factor
282 filamin A [12]. We showed that *Toxoplasma* alters the morphology of its host cells through
283 IRE1-filamin A interactions, which directs cytoskeletal remodeling that contributes to a
284 hypermigratory phenotype that facilitated dissemination of the parasite into multiple organs of
285 the infection host. The role of IRE1 in *Toxoplasma*-induced hypermigration is not reliant on its
286 protein kinase or endoribonuclease activities that are central for classical UPR signaling; rather,
287 it is IRE1 oligomerization and the C-terminal residues required for filamin A association that
288 prove to be important.

289 After oral infection, *Toxoplasma* rapidly spreads from the lamina propria to distal organs
290 using host immune cells as a vehicle for dissemination [22]. Given our discovery that IRE1 is
291 mobilized by *Toxoplasma* to enhance hypermigratory behavior in host cells, we tested whether
292 IRE1 is crucial to *in vivo* dissemination in a mouse model of infection. We found that depletion
293 of IRE1 in immune cells sharply decreases the number of parasites in the spleen or brain of
294 infected mice (**Fig. 5E**). These results reveal a number of potential new targets for drug
295 development aimed at thwarted spread of infection in the body.

296 It is noteworthy that other mechanisms have been suggested to contribute to the cell
297 hypermotility upon *Toxoplasma* infection. For example, parasite effector protein TgWIP, TIMP-
298 1, and GABAergic signaling were reported to signal hypermigration of certain infected host cells
299 [23-26]. A key question for future studies is how these different mechanisms are coordinated to
300 induce hypermigratory activity in *Toxoplasma*-infected host cells.

301

302

303

304 **Methods**

305 **Host cell and parasite culture.** MEF (mouse embryonic fibroblast) cells were cultured in
306 Dulbecco's modification of Eagle's medium (DMEM) supplemented with 10% heat-inactivated
307 fetal bovine serum (FBS) (Gibco/Invitrogen) and penicillin/streptomycin at 37°C with 5% CO₂.
308 *PERK*^{-/-} cells were previously reported [27] and IRE1-deficient MEF cells were engineered by
309 CRISPR as described below. Host cells were seeded at a density of 2x10⁵ cells/well in a 6 well
310 plate and cultured for 18 h. Infection was performed using multiplicity of infection (MOI) of 3
311 with Type I or II (RH or ME49) strain *Toxoplasma* parasites, as indicated, for 18 h. The infected
312 cells were cultured in DMEM medium supplemented with 10% heat-inactivated fetal bovine
313 serum (FBS) (Gibco/Invitrogen) and penicillin/streptomycin at 37°C with 5% CO₂. Cultures of
314 DCs and J774.1 macrophages were cultivated in Roswell Park Memorial Institute (RPMI)
315 supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco/Invitrogen) and
316 penicillin/streptomycin at 37°C with 5% CO₂ and infected as described above.

317

318 **Generation of *IRE1* knockout cells.** Disruption of the *IRE1* gene in MEF cells was carried out
319 using the CRISPR/Cas9 method [28]. Two distinct sgRNAs designed using DESKGEN™ tool
320 (g1-TGGACACGGAGCTGACT and g2-ACACGGAGCTGACTGGG) were examined
321 individually. The sgRNAs were prepared using the EnGen™ sgRNA Synthesis Kit (New
322 England BioLabs), along with a sg control (g-control- CATCCTCGGCACCGTCACCC). The
323 sgRNAs were then associated with EnGen® Spy Cas9 NLS protein (New England BioLabs) at
324 room temperature for 20 min. MEF cells were then transfected with the bound sgRNA/Cas9
325 protein using the Lipofectamine CRISPRMAX Cas9 Transfection Reagent (Thermo-Fisher
326 Scientific). After culturing the transfected cells for 48 h, 100 cells were plated in 10 mm tissue-

327 culture dishes for cloning. Cloned *IRE1*^{-/-} MEF cells were validated by RT-qPCR using specific
328 primers and by immunoblot using IRE1-specific antibody (Abcam-ab37073). *IRE1*^{-/-} cells were
329 complemented with pcDNA3-derived vectors containing WT or the indicated mutant versions of
330 *IRE1*. Briefly, the mouse cDNA sequence of *IRE1* from MEF cells was inserted into pcDNA3-
331 EGFP plasmid (Addgene #13031), resulting in fusion proteins with the EGFP fused to the
332 carboxy terminus of IRE1. Mutations in *IRE1* include changes inactivating the critical functions,
333 including *kD* (kinase domain- K599A), *eD* (endoribonuclease domain- P830L), *oD*
334 (oligomerization domain- D123P) or *c-terminal* (truncated c-terminal Δ 965), were carried out
335 using specific primers (**Supplemental Table 1**) and the Q5 Site-Directed Mutagenesis Kit (New
336 England Biolabs). After sequence verification, the plasmids were transfected into *IRE1*^{-/-} cells
337 using FuGENE 6 Transfection Reagent. Rescued WT and mutant IRE1 protein expression were
338 confirmed by immunoblot and immunofluorescence microscopy (**Fig. S4A and B**).

339 To generate bone marrow-derived dendritic cells (DCs), 10×10^6 bone marrow cells were
340 isolated and cultured in 6-well plate in 3 ml of complete medium (RPMI 1640 medium
341 supplemented with 10% fetal bovine serum, penicillin, streptomycin, glutamine, 2-
342 mercaptoethanol, 20 ng/ml granulocytes-macrophage colony-stimulating factor (GM-CSF) and
343 5ng/ml Interleukin 4 (IL-4) (both from Peprotech)) for 7 days. Half of the medium was replaced
344 every two days with medium supplemented with GM-CSF and IL-4, as previously described
345 [29]. DCs or J774.1 macrophages were transfected with IRE1-sgRNA-1 or 2, associated with
346 EnGen™ Spy Cas9 NLS protein (New England BioLabs), using the 4D-Nucleofector™ System
347 (Lonza) in combination with the P3 Primary Cell 4D-Nucleofector™ X Kit. After 48 h, the *IRE1*
348 mRNA and protein levels were measured by RT-qPCR and immunoblot, respectively. Viability
349 of DCs was examined by trypan blue staining.

350
351 **Measurement of mRNA levels.** Cells were first infected with *Toxoplasma* for 2 h, washed with
352 phosphate-buffered saline (PBS), and then cultured in DMEM at the indicated time points. RNA
353 was isolated from cells using TRIzol LS Reagent (Invitrogen™), the cDNA was then generated
354 using Omniscript (Qiagen) and RT-qPCR was performed using SYBR® Green Real-Time PCR
355 Master Mixes (Invitrogen™) and the StepOnePlus Real System (Applied Biosystems™).
356 Oligonucleotide primers used to measure each target mRNA is listed in the supplementary Table
357 1. Relative levels of target mRNAs from the uninfected samples were adjusted to 1 and served as
358 the basal control value. Values of each time point were normalized to mock infection. Each
359 experiment was performed three times, each with three technical replicates.

360
361 **Immunoblot analyses.** Cells were infected with *Toxoplasma* for 2 h, washed with PBS, then
362 cultured in DMEM for the indicated time points. The infected cells were harvested in RIPA
363 buffer solution supplemented with cOmplete™ and EDTA-free Protease Inhibitor Cocktail
364 (Roche). Protein quantification was performed using the Bradford Reagent (Sigma-Aldrich).
365 Equal amounts of protein lysates were separated by SDS-PAGE and proteins were transferred to
366 nitrocellulose filters. Immunoblot analyses were using primary antibodies- IRE1 (Abcam-
367 ab37073), XBP1s (Cell Signaling #D2C1F), ATF6 [30], GAPDH (Abcam-ab9485), PERK (Cell
368 Signaling #3192), followed by Amersham ECL HRP-Conjugated Antibodies secondary
369 antibody. These antibodies and additional reagents used in the study are listed in the
370 supplementary Table 2. Proteins were visualized in the immunoblots were visualized using
371 FluorChem M- Multiplex fluorescence (Protein Simple). Immunoblot analyses were carried out
372 for three independent experiments.

373

374 **Calcium measurement assay.** *Toxoplasma*-infected MEF cells were washed twice with buffer
375 A solution supplemented with glucose (120 mM NaCl, 20 mM HEPES (pH 7.4), 4.7 mM KCl,
376 1.2 mM NaH₂PO₄, 1.2 mM MgSO₄, 1.2 mM CaCl₂ and 10 mM glucose) [31], and then a final
377 concentration of 5 μM of Fluo-4, AM (Thermo Fisher Scientific, F14201) was added for 15 min
378 at 37°C. Prior to the calcium measurements, cells were washed once with buffer A solution
379 supplemented with glucose. A Synergy (BioTek) plate reader was used to monitor the Fluo-4
380 AM fluorescence at 488-nm excitation and 524-nm emission wavelengths. Values derived from
381 infected cells (ΔF) were divided by the resting intracellular calcium (F₀), $\Delta F/F_0$, and the values
382 of each time point were normalized to mock-infected cells. In parallel, live infected cells were
383 imaged by microscopy at the same exposure and a heat map was generated using ImageJ
384 software. To determine the activity of RyR and IP₃R receptors, infected cells were incubated
385 with 5 μM Mag-Fluo-4, a low-affinity Ca²⁺ indicator, then permeabilized with 10 μg/ml of
386 saponin followed by incubation with 1.5 mM ATP to maintain Mag-Fluo-4 in the ER [19] (**Fig.**
387 **S2B**). Infected cells were treated with the indicated concentrations of caffeine (RyR, 0-200 mM)
388 or IP₃ (IP₃R, 0-3 μM) (Sigma-Aldrich). A Synergy (BioTek) plate reader was used to monitor the
389 Mag-Fluo-4 fluorescence at 490-nm excitation and 525-nm emission wavelengths [19]. Values
390 were normalized to mock-infected cells.

391

392 **Immunofluorescence assay.** Cultured cells were infected with *Toxoplasma* for 18 h, then fixed
393 with 2.5% paraformaldehyde for 20 min and blocked with PBS supplemented with 2% BSA.
394 Cells were permeabilized in blocking solution containing 0.01% Triton X-100 for 30 min, and
395 incubated with primary antibody (SAG1-p30, Invitrogen) for 1 h. Secondary goat anti-rabbit

396 Alexa-fluor 488 (Invitrogen) was applied for 1 h in the presence of Rhodamine Phalloidin
397 (Thermo Fisher Scientific) followed by Prolong Gold antifade reagent (Invitrogen). DAPI was
398 used to visualize host cells and parasite nuclei (Vector Labs). Images were acquired with a Leica
399 inverted DMI6000B microscope with 63x oil immersion objective and analyzed in ImageJ.
400 Alternatively, *IRE1*^{-/-} cells were transfected with pcDNA3 encoding IRE1 fused with EGFP at
401 the carboxy terminus and infected with *Toxoplasma* for 18h (MOI: 3); the cells were then fixed
402 and imaged as described above.

403
404 **Immunoprecipitation assay.** The mouse cDNA sequence of filamin A from MEF cells was
405 amplified and cloned into pcDNA3-myc plasmid (Addgene). The resulting plasmid pcDNA3-
406 myc-FLNA was transiently transfected in the MEF cells and then the transfected cells were
407 infected with *Toxoplasma* for 18 h (MOI: 3). Cell lysates were prepared using IP-lysis solution
408 (0.5% NP-40, 250 mM NaCl, 30 mM Tris, 0.5% glycerol, pH 7.4, 250 mM phenylmethylsulfonyl
409 fluoride (PMSF) supplemented with cOmplete™ and EDTA-free Protease Inhibitor Cocktail
410 (Roche)). To immunoprecipitate myc-tagged filamin A (myc-filamin A), equal amounts of
411 protein lysates were incubated with IgG Magnetic beads (Pierce) for 2 h, then mixed with anti-
412 myc Magnetic beads (Pierce) overnight at 4 °C with rotation. Proteins bound to the beads were
413 subsequently washed four times with IP-lysis solution at 4°C and then once with IP-lysis
414 solution supplemented with 500 mM NaCl. Protein complexes were eluted at 95°C for 5 min in
415 loading buffer solution and then separated by SDS-PAGE, followed by immunoblot analyses
416 using specific antibodies to IRE1 (Abcam-ab37073) or Myc (Cell Signaling #2276).

417

418 **Cell migration assay.** Cells were infected with *Toxoplasma* MOI 3 for 18 h and then trypsinized
419 and counted using a hemocytometer; 2×10^4 cells were resuspended in serum-free medium and
420 applied to the top of a membrane coated with collagen I (rat-tail) (Gibco- A1048301).
421 Transmigration assays were carried out using a Corning Transwell Costar apparatus (6.5 mm
422 diameter and 8 μ m pore size) as described [32]. After 18 h for MEF and 6 h for DCs and
423 macrophages, the medium was removed, and the cells were fixed with 2.5% paraformaldehyde
424 for 20 min. To facilitate counting of migrated cells, cells that did not migrate and remained on
425 the upper side of membrane (unmigrated cells) were removed with a swab. The membrane was
426 incubated with Prolong Gold antifade reagent with DAPI. Cells were counted using a Leica
427 inverted DMI6000B microscope with 63x oil immersion objective. The transmigration was
428 determined by numbers of migrated infected cells in 5 fields normalized to number of uninfected
429 cells. Each transmigration assay was carried out in technical triplicate in $n=3$.

430
431 ***In vivo* migration assay.** DCs were plated in 6-well plates (1×10^6 cells/well) and allowed to
432 adhere overnight. DCs were infected with *Toxoplasma* for 1 h (MOI: 3) and then washed with
433 RPMI to remove extracellular parasites. After 18 h, infected DCs were incubated with
434 CellTracker™ Orange CMTMR (Thermo Fisher) as described [33]. Infected DCs were
435 intraperitoneally inoculated into 6-weeks-old female C57BL/6J mice whose spleens and brains
436 were subsequently harvested at the indicated time points and the DC migration to the spleen was
437 measured by the fluorescence intensity at the indicated time points using a Synergy (BioTek)
438 plate reader at ex/em 541/565 nm (**Fig. S5C**). Also, DNA was isolated from the spleen and brain
439 using TRIzol (Thermo Fisher), and the number of parasites was determined by using a PCR-
440 based method measuring levels of the parasite-specific gene region B1 as previously described

441 [34]. After 3 days, the mice were observed twice a day and percent survival was recorded at each
442 time point. The mice experiment, including parasite measurement by B1 were performed on
443 blinded. The mice used in this study were housed in American Association for Accreditation of
444 Laboratory Animal Care (AAALAC)-approved facilities at the Indiana University School of
445 Medicine Laboratory Animal Research Center (LARC). The Institutional Animal Care and Use
446 Committee (IACUC) at Indiana University School of Medicine approved the use of all animals
447 and procedures (IACUC protocol number 11376).

448

449 **Quantification and statistical analysis.** Quantitative data were presented as the mean and
450 standard deviation and were derived from three biological replicates. Statistical significance was
451 determined using One-way ANOVA with Tukey's post hoc test and multiple t-test two-tailed
452 using Graph Prism software. The number of biological replicates (n) and p-values are indicated
453 in figure legends. For immunoblot analyses, the reported images are representative of at least
454 three independent experiments. The mice survival curve was analyzed by Gehan-Breslow-
455 Wilcoxon test for *in vivo* analysis.

456 **Acknowledgments**

457 This research was supported by a research grant from National Institutes of Health (AI124723 to
458 W.J.S. and R.C.W.). R.C.W. receives financial support from HiberCell. M.H.K. and N.S.A. were
459 supported by funds from the Brown Center for Immunotherapy. J.M. was supported by PHS
460 grant T32 AI060519 and the Joseph and Lucille Madri Family Scholarship. The authors would
461 like to thank Drs. Tatiana Clemente and Stacey Gilk, as well as our lab members for helpful
462 discussions.

463

464 **Contributions**

465 Study design and planning: L.A., J.M., P.H.A., M.H.K, R.C.W. and W.J.S. Performed
466 experiments and generated reagents: L.A., J.M., P.H.A. and N.S.A. Data analysis: L.A., J.M. and
467 P.H.A. Manuscript writing: L.A., R.C.W. and W.J.S. Manuscript was drafted with input from all
468 authors.

469

470 **Competing interests**

471 The authors declare no competing interests.

472 **References**

- 473 1. Hakimi, M.A. et al. (2017) Toxoplasma Effectors Targeting Host Signaling and
474 Transcription. *Clin Microbiol Rev* 30 (3), 615-645.
- 475 2. Jeffers, V. et al. (2018) A latent ability to persist: differentiation in *Toxoplasma gondii*.
476 *Cell Mol Life Sci* 75 (13), 2355-2373.
- 477 3. Blader, I.J. and Koshy, A.A. (2014) *Toxoplasma gondii* development of its replicative
478 niche: in its host cell and beyond. *Eukaryot Cell* 13 (8), 965-76.
- 479 4. Sinai, A.P. et al. (1997) Association of host cell endoplasmic reticulum and mitochondria
480 with the *Toxoplasma gondii* parasitophorous vacuole membrane: a high affinity interaction. *J*
481 *Cell Sci* 110 (Pt 17), 2117-28.
- 482 5. Coppens, I. and Romano, J.D. (2018) Hostile intruder: *Toxoplasma* holds host organelles
483 captive. *PLoS Pathog* 14 (3), e1006893.
- 484 6. Walter, P. and Ron, D. (2011) The unfolded protein response: from stress pathway to
485 homeostatic regulation. *Science* 334 (6059), 1081-6.
- 486 7. Karagoz, G.E. et al. (2019) The Unfolded Protein Response: Detecting and Responding
487 to Fluctuations in the Protein-Folding Capacity of the Endoplasmic Reticulum. *Cold Spring Harb*
488 *Perspect Biol* 11 (9).
- 489 8. Hetz, C. and Papa, F.R. (2018) The Unfolded Protein Response and Cell Fate Control.
490 *Mol Cell* 69 (2), 169-181.
- 491 9. Mori, K. (2010) Divest yourself of a preconceived idea: transcription factor ATF6 is not a
492 soluble protein! *Mol Biol Cell* 21 (9), 1435-8.
- 493 10. Wek, R.C. (2018) Role of eIF2alpha Kinases in Translational Control and Adaptation to
494 Cellular Stress. *Cold Spring Harb Perspect Biol* 10 (7).

- 495 11. Chang, T.K. et al. (2018) Coordination between Two Branches of the Unfolded Protein
496 Response Determines Apoptotic Cell Fate. *Mol Cell* 71 (4), 629-636 e5.
- 497 12. Urrea, H. et al. (2018) IRE1alpha governs cytoskeleton remodelling and cell migration
498 through a direct interaction with filamin A. *Nat Cell Biol* 20 (8), 942-953.
- 499 13. Bierly, A.L. et al. (2008) Dendritic cells expressing plasmacytoid marker PDCA-1 are
500 Trojan horses during *Toxoplasma gondii* infection. *J Immunol* 181 (12), 8485-91.
- 501 14. Korennykh, A.V. et al. (2009) The unfolded protein response signals through high-order
502 assembly of Ire1. *Nature* 457 (7230), 687-93.
- 503 15. Aragon, T. et al. (2009) Messenger RNA targeting to endoplasmic reticulum stress
504 signalling sites. *Nature* 457 (7230), 736-40.
- 505 16. Li, H. et al. (2010) Mammalian endoplasmic reticulum stress sensor IRE1 signals by
506 dynamic clustering. *Proc Natl Acad Sci U S A* 107 (37), 16113-8.
- 507 17. Carreras-Sureda, A. et al. (2018) Calcium signaling at the endoplasmic reticulum: fine-
508 tuning stress responses. *Cell Calcium* 70, 24-31.
- 509 18. Carreras-Sureda, A. et al. (2019) Non-canonical function of IRE1alpha determines
510 mitochondria-associated endoplasmic reticulum composition to control calcium transfer and
511 bioenergetics. *Nat Cell Biol* 21 (6), 755-767.
- 512 19. Yamamoto, W.R. et al. (2019) Endoplasmic reticulum stress alters ryanodine receptor
513 function in the murine pancreatic beta cell. *J Biol Chem* 294 (1), 168-181.
- 514 20. Weidner, J.M. et al. (2013) Rapid cytoskeleton remodelling in dendritic cells following
515 invasion by *Toxoplasma gondii* coincides with the onset of a hypermigratory phenotype. *Cell*
516 *Microbiol* 15 (10), 1735-52.

- 517 21. Zhou, A.X. et al. (2010) Filamins in cell signaling, transcription and organ development.
518 Trends Cell Biol 20 (2), 113-23.
- 519 22. Drewry, L.L. and Sibley, L.D. (2019) The hitchhiker's guide to parasite dissemination.
520 Cell Microbiol, e13070.
- 521 23. Olafsson, E.B. et al. (2019) TIMP-1 promotes hypermigration of Toxoplasma-infected
522 primary dendritic cells via CD63-ITGB1-FAK signaling. J Cell Sci 132 (3).
- 523 24. Bhandage, A.K. et al. (2019) Toxoplasma-Induced Hypermigration of Primary Cortical
524 Microglia Implicates GABAergic Signaling. Front Cell Infect Microbiol 9, 73.
- 525 25. Bhandage, A.K. and Barragan, A. (2019) Calling in the CaValry-Toxoplasma gondii
526 Hijacks GABAergic Signaling and Voltage-Dependent Calcium Channel Signaling for Trojan
527 horse-Mediated Dissemination. Front Cell Infect Microbiol 9, 61.
- 528 26. Sangare, L.O. et al. (2019) In Vivo CRISPR Screen Identifies TgWIP as a Toxoplasma
529 Modulator of Dendritic Cell Migration. Cell Host Microbe 26 (4), 478-492.e8.
- 530 27. Jiang, H.Y. et al. (2004) Activating transcription factor 3 is integral to the eukaryotic
531 initiation factor 2 kinase stress response. Mol Cell Biol 24 (3), 1365-77.
- 532 28. Cong, L. et al. (2013) Multiplex genome engineering using CRISPR/Cas systems.
533 Science 339 (6121), 819-23.
- 534 29. Inaba, K. et al. (2001) Isolation of dendritic cells. Curr Protoc Immunol Chapter 3, Unit
535 3.7.
- 536 30. Teske, B.F. et al. (2011) The eIF2 kinase PERK and the integrated stress response
537 facilitate activation of ATF6 during endoplasmic reticulum stress. Mol Biol Cell 22 (22), 4390-
538 405.

- 539 31. Borges-Pereira, L. et al. (2015) Calcium Signaling throughout the *Toxoplasma gondii*
540 Lytic Cycle: A STUDY USING GENETICALLY ENCODED CALCIUM INDICATORS. *J*
541 *Biol Chem* 290 (45), 26914-26.
- 542 32. Lechuga, S. et al. (2019) Adducins inhibit lung cancer cell migration through
543 mechanisms involving regulation of cell-matrix adhesion and cadherin-11 expression. *Biochim*
544 *Biophys Acta Mol Cell Res* 1866 (3), 395-408.
- 545 33. Lambert, H. et al. (2006) Induction of dendritic cell migration upon *Toxoplasma gondii*
546 infection potentiates parasite dissemination. *Cell Microbiol* 8 (10), 1611-23.
- 547 34. Kompalic-Cristo, A. et al. (2007) Evaluation of a real-time PCR assay based on the
548 repetitive B1 gene for the detection of *Toxoplasma gondii* in human peripheral blood. *Parasitol*
549 *Res* 101 (3), 619-25.
- 550
- 551

552 **Figure Legends**

553 **Figure 1. *Toxoplasma* infection triggers activation of the UPR in host cells.** (A) At the
554 indicated times following infection with *Toxoplasma*, cells were harvested and the levels of total
555 PERK, PERK-P, full length ATF6 and ATF6-N, XBP1s, and GAPDH were measured by
556 immunoblot analyses. (B) *IRE1*^{-/-} MEF cells were transfected with a plasmid encoding EGFP-
557 IRE1 (green), followed by infection with *Toxoplasma*. DAPI (blue) was used to visualize host
558 cell and parasites nuclei. Two boxed areas (1 and 2) of each condition are amplified to highlight
559 the IRE1 distribution. Bar=5 μm. (C) MEF cells were infected with *Toxoplasma* for 18 h, or
560 were mock infected, and the mRNA levels of the indicated ERAD/chaperone genes were
561 measured by RT-qPCR. Levels of mRNA were normalized to mock infected, which is
562 represented as a value of 1. (±SD, n=3) ***p<0.001, ****p<0.0001. (D) *XBP1s* mRNA levels
563 were measured by RT-qPCR at the indicated hpi in WT, *PERK*^{-/-} and *IRE1*^{-/-} MEF cells, as
564 indicated. Levels of *XBP1s* mRNA were normalized to total *XBP1* mRNA in mock infected cells
565 (value of 1) at each time point. (±SD, n=3) ****p<0.0001.

566
567 **Figure 2. *Toxoplasma* infection induces calcium release.** (A) At the indicated time hpi,
568 cytosolic calcium levels were measured in the infected WT and *IRE1*^{-/-} cells. Values of infected
569 cells were normalized to mock-infected cells (±SD, n=3), **p<0.005 and ****p<0.001. (B)
570 Infected WT and *IRE1*^{-/-} cells were treated with RyR or IP₃R inhibitors for 6 h and the levels of
571 cytosolic calcium were measured. 100 μM Ryanodine (RyR inhibitor) and 0.6 μM Xestospongin
572 C (XeC) (IP₃R inhibitor), (±SD, n=3) **p<0.05, ***p<0.005. Infected cells were incubated with
573 Mag-Fluo-4, followed by plasma membrane permeabilization with saponin and incubation with
574 ATP to maintain the calcium in the ER. To estimate RyR (C) and IP₃R (D) activity, WT and

575 *IRE1*^{-/-} cells infected with *Toxoplasma* for 18 h were treated with caffeine or IP₃ at the indicated
576 concentrations and calcium release is represented the fluorescence using Mag-Fluo-4 as
577 described [19]. Values are represented as the percentage of calcium release and the respective
578 start points were normalized to untreated WT and *IRE1*^{-/-} cells, respectively. (±SD, n=3),
579 **p<0.05, ****p<0.001.

580
581 **Figure 3. Activation of IRE1 enhances migration of cells infected with *Toxoplasma*.** (A) The
582 numbers of lamellipodia were determined in 50 randomly selected MEF cells infected with
583 *Toxoplasma* 18 hpi and normalized to uninfected cells. Also shown are infected WT cells treated
584 with 1.2 μM PERKi (GSK2656157), 0.4 μM 4μ8c, 250 nM KIRA6, or 0.2 μM ceapin-A7 for 18
585 h. (±SD, n=5) **p<0.05, ***p<0.005. (B) WT and *IRE1*^{-/-} cells were infected with *Toxoplasma*
586 for 18 h, then cells were harvested and the levels of filamin A phosphorylation (S2152) were
587 measured by immunoblot analyses. (C) WT cells transiently expressing Myc-filamin A were
588 infected with *Toxoplasma* for 18 h. IP of the tagged Filamin A was carried out using Myc
589 magnetic beads. Bound proteins were separated by SDS-PAGE and the levels of Myc-filamin A
590 and associated IRE1 were measured by immunoblot and compared to uninfected cells.
591 Densitometry of IRE1 signal divided by Myc signal (IRE1/Myc). (D) WT or *IRE1*^{-/-}, *PERK*^{-/-},
592 and *XBPI*^{-/-} cells were infected with *Toxoplasma* for 18 h. Alternatively, WT cells were infected
593 with parasite and treated with the following inhibitors during migration per 18 h: 1.2 μM PERKi
594 (GSK2656157), 0.2 μM Ceapin-A7, 250 nM KIRA6, or 0.4 μM 4μ8c. Infected and mock
595 infected cells were trypsinized, counted, and the same number of cells was used for the
596 transmigration assay. Transmigration was determined by counting the number of infected
597 normalized to noninfected cells that migrated through the membrane. (±SD n=3), *** p<0.0005.

598 (E) *IRE1*^{-/-} cells were rescued with *ire1-wt* (wild-type), *kD* (kinase domain-dead- K599A), *eD*
599 (endoribonuclease domain-dead- P830L), *oD* (oligomerization domain-dead- D123P) or *Δ965*
600 (truncated c-terminal *Δ965*), and then a transmigration assay was carried out as described above.
601 (\pm SD, n=3), ****p<0.0001. (F) Transmigration assay of infected WT MEF cells was carried out
602 in the presence of IP₃R and RyR inhibitors (0.6 μ M Xestospongine C, XeC or 100 μ M
603 Ryanodine, Ry) or activators (100 μ M IP₃ or 1 mM caffeine). (\pm SD, n=3), *p<0.1, **p<0.05 and
604 ***p<0.0005. ns = not significant.

605
606 **Figure. 4. IRE1 is important for migration of infected DCs.** (A) Bone marrow-derived DCs
607 were infected with *Toxoplasma* for 18 h and *XBP1s* mRNA levels were measured by RT-qPCR.
608 The values of *XBP1s* were normalized to values of total *XBP1*. (\pm SD, n=3) ***p<0.0005. (B-C)
609 The CRISPR/Cas9-engineered depletion of IRE1 in DCs, designated *ire* (-), was assayed by RT-
610 qPCR and immunoblot using IRE1 antibody compared to WT cells (GAPDH was included as a
611 loading control). (D) Percentage of infection was determined by counting the number of parasites
612 inside 100 WT or *ire1* (-) cells. (E) WT and *ire1* (-) cells were infected for 18 h and the
613 transmigration assay was carried out for 6 h. Transmigration was determined by counting the
614 number of infected cells normalized to noninfected cells. (\pm SD, n=3), **p<0.05 and
615 ***p<0.0005. (F) WT-DCs were infected for 18 h and the transmigration assay was carried out
616 in presence of 0.6 μ M xestospongine C (XeC) for 6 h (\pm SD, n=3), ***p<0.001. (G-H) J774.1
617 macrophages were transfected with sgRNA-2 and the depletion of IRE1 was assayed by RT-
618 qPCR and immunoblot as described in (C). (I) At 18 hpi, WT or *ire1* (-) J774.1 macrophages
619 were assayed for transmigration as described above. (\pm SD, n=3), **p<0.05.

620

621 **Figure. 5. IRE1 facilitates migration of infected DCs *in vivo*.** (A-B) IRE1 was depleted in
622 bone marrow-derived DCs by CRISPR/Cas9 and loss of *IRE1* expression was assayed by RT-
623 qPCR and immunoblot analyses. (C) WT or *ire1* (-) DCs were infected for 18 h and the
624 percentage of infection was determined by counting the number of parasites in 100 cells. (D)
625 Infected WT and *ire1* (-) cells were inoculated into mice by i.p. injection (10^6 infected cells). At
626 the indicated hpi, the spleen of each mouse was harvested, and the number of parasites was
627 determined by PCR. *** $p < 0.005$ and **** $p < 0.0001$. (E) At 3 days post inoculation, the number
628 of parasites was determined in the brain using PCR. **** $p < 0.0001$. (F) Survival of C57BL/6
629 mice challenged with 10^6 infected WT or *ire1* (-) DCs. *** $p < 0.0005$. Statistical analyses by
630 Gehan-Breslow-Wilcoxon test. (G) Model for IRE1-direct hypermigration of host cells infected
631 by *Toxoplasma*. During infection, *Toxoplasma* triggers calcium release from the host ER, which
632 creates ER stress and induction of the UPR, which results in enhanced IRE1 association with
633 filamin A. Consequently, the IRE1-filamin A interaction promotes actin remodeling and host cell
634 migration.

635 **Supplemental Figure Legends**

636 **Supplemental Figure. 1.** MEF cells were transfected with Cas9 bound to sgRNA targeted to
637 IRE1 as described in the methods section; lowered *IRE1* expression resulting from the
638 CRISPR/Cas9 gene editing was evaluated by (A) RT-qPCR and (B) immunoblot analyses.
639 GAPDH was included as a loading control for the immunoblot analyses. (C) WT and *IRE1*^{-/-}
640 MEF cells were treated with 1 μM thapsigargin (TG), or no stress agent, for 6 h. Cells were then
641 harvested and the *XBPIs* mRNA levels were measured by RT-qPCR. The values of *XBPIs*
642 mRNAs were normalized to values of total *XBPI* transcripts. (±SD, n=3) ***p<0.0005.

643
644 **Supplemental Figure. 2.** (A) MEF cells were infected with *Toxoplasma* for 18 h and then were
645 incubated with calcium indicator Fluo-4. Fluo-4 intensity is shown as a heat map, with yellow
646 showing the highest Fluo-4 intensity and blue showing the lowest Fluo-4 intensity. (B) WT and
647 *IRE1*^{-/-} cells were transfected with mCherry-ER-KDEL (a marker for the ER) and infected for 18
648 h with *Toxoplasma*. Cells were then loaded with the low-affinity Ca²⁺ indicator Mag-Fluo-4 AM
649 (green) and the plasma membrane was permeabilized, resulting in Mag-Fluo-4 AM retainment in
650 the ER. Note that the Mag-Fluo-4 AM (green) co-localizes with mCherry-ER-KDEL (red).

651
652 **Supplemental Figure. 3.** (A) WT cells were infected with *Toxoplasma* for 18 h, then fixed with
653 paraformaldehyde and incubated with SAG1 antibody to detect parasites (green); phalloidin
654 shows actin (red) and DAPI shows nuclei (blue). The arrows show lamellipodia at edge of cells.
655 (B) At 18 hpi, infected and uninfected cells were trypsinized and counted, and the same number
656 of cells were used in the transmigration assay. Transmigration was determined by counting the
657 number of cells that transmigrated through membrane. (±SD, n=3), *p<0.05, ***p<0.0005 and


658 ****p<0.0001. ns = not significant. (C) WT and *IRE1*^{-/-} MEF cells were infected using ME49
659 (type II) strain for 18h and transmigration was determined by counting the number of infected
660 cells normalized to noninfected cells (\pm SD, n=3), ****p<0.0001. (D) WT and *ire1* (-) DCs were
661 infected with ME49 strain for 18 h and transmigration was determined by counting the number
662 of infected cells normalized to noninfected cells for 6 h (\pm SD, n=3), ***p<0.0005.

663
664 **Supplemental Figure. 4.** (A) *IRE1*^{-/-} MEF cells were rescued with WT and mutant versions of
665 transient expression *IRE1* (green), then cells were fixed and stained using KDEL antibody as an
666 ER marker (red); DAPI was used as to visualize nuclei (blue). *Ire1-wt*, *ire1-kD*: kinase domain
667 dead, *ire1-eD*: endoribonuclease dead, *ire1-oD*: *ire1-Δ965* deletion of filamin A binding site
668 [12]. (B) Lysates were prepared from the cells and IRE1, GFP, or actin protein levels were
669 measured by immunoblot analyses using specific antibodies. (C) WT or *IRE1*^{-/-} MEF cells that
670 were rescued with the indicated *IRE1* alleles were cultured in the presence or absence of 1 μ M
671 thapsigargin for 6 h and *XBPIs* mRNA levels were measured by RT-qPCR. Values of *XBPIs*
672 mRNA were normalized to total *XBPI* mRNA levels for each condition. (\pm SD, n=3),
673 ***p<0.0005.

674
675 **Supplemental Figure. 5.** (A) Schematic of IRE1-sgRNAs (1 and 2) and the gene region that was
676 amplified by RT-qPCR to verify loss of *IRE1* expression. (B) Viability assay of DCs at
677 designated hours post-transfection with gRNA-IRE1 (*ire1* (-)) or random gRNA (WT). (C)
678 Infected WT and *ire1* (-) DCs were incubated with cell tracker and then inoculated into mice by
679 i.p. injection using 10⁶ infected cells. At the indicated hpi, the spleen of each mouse was

680 harvested and the cell tracker fluorescence was measured using a plate reader. Values of
681 fluorescence were normalized to uninfected (fold change). ** $p < 0.01$ and **** $p < 0.0001$.
682

Fig.1



683

684 **Figure. 1. *Toxoplasma* infection triggers activation of the UPR in host cells.** (A) At the
 685 indicated times following infection with *Toxoplasma*, cells were harvested and the levels of total
 686 PERK, PERK-P, full length ATF6 and ATF6-N, XBP1s, and GAPDH were measured by
 687 immunoblot analyses. (B) *IRE1*^{-/-} MEF cells were transfected with a plasmid encoding EGFP-
 688 IRE1 (green), followed by infection with *Toxoplasma*. DAPI (blue) was used to visualize host
 689 cell and parasites nuclei. Two boxed areas (1 and 2) of each condition are amplified to highlight

690 the IRE1 distribution. Bar=5 μ m. (C) MEF cells were infected with *Toxoplasma* for 18 h, or
691 were mock infected, and the mRNA levels of the indicated ERAD/chaperone genes were
692 measured by RT-qPCR. Levels of mRNA were normalized to mock infected, which is
693 represented as a value of 1. (\pm SD, n=3) ***p<0.001, ****p<0.0001. (D) *XBPIs* mRNA levels
694 were measured by RT-qPCR at the indicated hpi in WT, *PERK*^{-/-} and *IRE1*^{-/-} MEF cells, as
695 indicated. Levels of *XBPIs* mRNA were normalized to total *XBPI* mRNA in mock infected cells
696 (value of 1) at each time point. (\pm SD, n=3) ****p<0.0001.

697

698

699

700

701

702

703

704

705

706


707

708

709

710

Fig. 2



711

712 **Figure 2. Toxoplasma infection induces calcium release.** (A) At the indicated time hpi,

713 cytosolic calcium levels were measured in the infected WT and *IRE1*^{-/-} cells. Values of infected

714 cells were normalized to mock-infected cells (\pm SD, n=3), **p<0.005 and ****p<0.001. (B)

715 Infected WT and *IRE1*^{-/-} cells were treated with RyR or IP₃R inhibitors for 6 h and the levels of

716 cytosolic calcium were measured. 100 μ M Ryanodine (RyR inhibitor) and 0.6 μ M Xestospongin

717 C (XeC) (IP₃R inhibitor), (\pm SD, n=3) **p<0.05, ***p<0.005. Infected cells were incubated with

718 Mag-Fluo-4, followed by plasma membrane permeabilization with saponin and incubation with

719 ATP to maintain the calcium in the ER. To estimate RyR (C) and IP₃R (D) activity, WT and

720 *IREI*^{-/-} cells infected with *Toxoplasma* for 18 h were treated with caffeine or IP₃ at the indicated
721 concentrations and calcium release is represented the fluorescence using Mag-Fluo-4 as
722 described [19]. Values are represented as the percentage of calcium release and the respective
723 start points were normalized to untreated WT and *IREI*^{-/-} cells, respectively. (\pm SD, n=3),
724 **p<0.05, ****p<0.001.

725

726

727

728

729

730

731

732

733

734

735

736

737

738


739

740

741

742

Fig. 3



743

744 **Figure 3. Activation of IRE1 enhances migration of cells infected with *Toxoplasma*.** (A) The
 745 numbers of lamellipodia were determined in 50 randomly selected MEF cells infected with
 746 *Toxoplasma* 18 hpi and normalized to uninfected cells. Also shown are infected WT cells treated
 747 with 1.2 μ M PERKi (GSK2656157), 0.4 μ M 4 μ 8c, 250 nM KIRA6, or 0.2 μ M ceapin-A7 for 18


748 h. (\pm SD, n=5) **p<0.05, ***p<0.005. (B) WT and *IRE1*^{-/-} cells were infected with *Toxoplasma*
749 for 18 h, then cells were harvested and the levels of filamin A phosphorylation (S2152) were
750 measured by immunoblot analyses. (C) WT cells transiently expressing Myc-filamin A were
751 infected with *Toxoplasma* for 18 h. IP of the tagged Filamin A was carried out using Myc
752 magnetic beads. Bound proteins were separated by SDS-PAGE and the levels of Myc-filamin A
753 and associated IRE1 were measured by immunoblot and compared to uninfected cells.
754 Densitometry of IRE1 signal divided by Myc signal (IRE1/Myc). (D) WT or *IRE1*^{-/-}, *PERK*^{-/-},
755 and *XBPI*^{-/-} cells were infected with *Toxoplasma* for 18 h. Alternatively, WT cells were infected
756 with parasite and treated with the following inhibitors during migration per 18 h: 1.2 μ M PERKi
757 (GSK2656157), 0.2 μ M Ceapin-A7, 250 nM KIRA6, or 0.4 μ M 4 μ 8c. Infected and mock
758 infected cells were trypsinized, counted, and the same number of cells was used for the
759 transmigration assay. Transmigration was determined by counting the number of infected
760 normalized to noninfected cells that migrated through the membrane. (\pm SD n=3), *** p<0.0005.
761 (E) *IRE1*^{-/-} cells were rescued with *ire1-wt* (wild-type), *kD* (kinase domain-dead- K599A), *eD*
762 (endoribonuclease domain-dead- P830L), *oD* (oligomerization domain-dead- D123P) or *Δ 965*
763 (truncated c-terminal *Δ 965*), and then a transmigration assay was carried out as described above.
764 (\pm SD, n=3), ****p<0.0001. (F) Transmigration assay of infected WT MEF cells was carried out
765 in the presence of IP₃R and RyR inhibitors (0.6 μ M Xestospongine C, XeC or 100 μ M
766 Ryanodine, Ry) or activators (100 μ M IP₃ or 1 mM caffeine). (\pm SD, n=3), *p<0.1, **p<0.05 and
767 ***p<0.0005. ns = not significant.

768

769

770

Fig. 4



771

772 **Figure 4. IRE1 is important for migration of infected DCs.** (A) Bone marrow-derived DCs

773 were infected with *Toxoplasma* for 18 h and *XBP1s* mRNA levels were measured by RT-qPCR.

774 The values of *XBP1s* were normalized to values of total *XBP1*. (\pm SD, n=3) ***p<0.0005. (B-C)

775 The CRISPR/Cas9-engineered depletion of IRE1 in DCs, designated ire (-), was assayed by RT-
776 qPCR and immunoblot using IRE1 antibody compared to WT cells (GAPDH was included as a
777 loading control). (D) Percentage of infection was determined by counting the number of parasites
778 inside 100 WT or ire1 (-) cells. (E) WT and ire1 (-) cells were infected for 18 h and the
779 transmigration assay was carried out for 6 h. Transmigration was determined by counting the
780 number of infected cells normalized to noninfected cells. (\pm SD, n=3), **p<0.05 and
781 ***p<0.0005. (F) WT-DCs were infected for 18 h and the transmigration assay was carried out
782 in presence of 0.6 μ M xestospongine C (XeC) for 6 h (\pm SD, n=3), ***p<0.001. (G-H) J774.1
783 macrophages were transfected with sgRNA-2 and the depletion of IRE1 was assayed by RT-
784 qPCR and immunoblot as described in (C). (I) At 18 hpi, WT or ire1 (-) J774.1 macrophages
785 were assayed for transmigration as described above. (\pm SD, n=3), **p<0.05.

786

787

788

789

790

791

792

793


794

795

796

797

Fig.5



798

799 **Figure 5. IRE1 facilitates migration of infected DCs *in vivo*.** (A-B) IRE1 was depleted in
800 bone marrow-derived DCs by CRISPR/Cas9 and loss of *IRE1* expression was assayed by RT-

801 qPCR and immunoblot analyses. (C) WT or ire1 (-) DCs were infected for 18 h and the
802 percentage of infection was determined by counting the number of parasites in 100 cells. (D)
803 Infected WT and ire1 (-) cells were inoculated into mice by i.p. injection (10^6 infected cells). At
804 the indicated hpi, the spleen of each mouse was harvested, and the number of parasites was
805 determined by PCR. *** $p < 0.005$ and **** $p < 0.0001$. (E) At 3 days post inoculation, the number
806 of parasites was determined in the brain using PCR. **** $p < 0.0001$. (F) Survival of C57BL/6
807 mice challenged with 10^6 infected WT or ire 1 (-) DCs. *** $p < 0.0005$. Statistical analyses by
808 Gehan-Breslow-Wilcoxon test. (G) Model for IRE1-direct hypermigration of host cells infected
809 by *Toxoplasma*. During infection, *Toxoplasma* triggers calcium release from the host ER, which
810 creates ER stress and induction of the UPR, which results in enhanced IRE1 association with
811 filamin A. Consequently, the IRE1-filamin A interaction promotes actin remodeling and host cell
812 migration.

813

814

815

816

817

818

819


820

821

822

823

Supplemental Fig. 1



824

825 **Supplemental Figure 1.** MEF cells were transfected with Cas9 bound to sgRNA targeted to

826 IRE1 as described in the methods section; lowered *IRE1* expression resulting from the

827 CRISPR/Cas9 gene editing was evaluated by (A) RT-qPCR and (B) immunoblot analyses.

828 GAPDH was included as a loading control for the immunoblot analyses. (C) WT and *IRE1*^{-/-}

829 MEF cells were treated with 1 μM thapsigargin (TG), or no stress agent, for 6 h. Cells were then

830 harvested and the *XBP1s* mRNA levels were measured by RT-qPCR. The values of *XBP1s*

831 mRNAs were normalized to values of total *XBP1* transcripts. (±SD, n=3) ***p<0.0005.

832

833

834

835


836

837

838

839

Supplemental Fig. 2



840

841 **Supplemental Figure. 2.** (A) MEF cells were infected with *Toxoplasma* for 18 h and then were
842 incubated with calcium indicator Fluo-4. Fluo-4 intensity is shown as a heat map, with yellow
843 showing the highest Fluo-4 intensity and blue showing the lowest Fluo-4 intensity. (B) WT and
844 *IRE1*^{-/-} cells were transfected with mCherry-ER-KDEL (a marker for the ER) and infected for 18

845 h with *Toxoplasma*. Cells were then loaded with the low-affinity Ca²⁺ indicator Mag-Fluo-4 AM
846 (green) and the plasma membrane was permeabilized, resulting in Mag-Fluo-4 AM retainment in
847 the ER. Note that the Mag-Fluo-4 AM (green) co-localizes with mCherry-ER-KDEL (red).

848

849

850

851

852

853

854

855

856

857

858

859

860

861


862

863

864

865

Supplemental Fig. 3



866

867 **Supplemental Figure 3.** (A) WT cells were infected with *Toxoplasma* for 18 h, then fixed with

868 paraformaldehyde and incubated with SAG1 antibody to detect parasites (green); phalloidin

869 shows actin (red) and DAPI shows nuclei (blue). The arrows show lamellipodia at edge of cells.

870 (B) At 18 hpi, infected and uninfected cells were trypsinized and counted, and the same number

871 of cells were used in the transmigration assay. Transmigration was determined by counting the

872 number of cells that transmigrated through membrane. (\pm SD, n=3), *p<0.05, ***p<0.0005 and

873 ****p<0.0001. ns = not significant. (C) WT and IRE1^{-/-} MEF cells were infected using ME49

874 (type II) strain for 18h and transmigration was determined by counting the number of infected
875 cells normalized to noninfected cells (\pm SD, n=3), ****p<0.0001. (D) WT and ire1 (-) DCs were
876 infected with ME49 strain for 18 h and transmigration was determined by counting the number
877 of infected cells normalized to noninfected cells for 6 h (\pm SD, n=3), ***p<0.0005.

878

879

880

881

882

883

884

885

886

887

888

889

890

891


892

893


894

Supplemental Fig. 4


A



B



C



895

896 **Supplemental Figure 4.** (A) *IRE1*^{-/-} MEF cells were rescued with WT and mutant versions of
 897 transient expression *IRE1* (green), then cells were fixed and stained using KDEL antibody as an
 898 ER marker (red); DAPI was used as to visualize nuclei (blue). *Ire1-wt*, *ire1-kD*: kinase domain
 899 dead, *ire1-eD*: endoribonuclease dead, *ire1-oD*: *ire1-Δ965* deletion of filamin A binding site

900 [12]. (B) Lysates were prepared from the cells and IRE1, GFP, or actin protein levels were
901 measured by immunoblot analyses using specific antibodies. (C) WT or *IRE1*^{-/-} MEF cells that
902 were rescued with the indicated *IRE1* alleles were cultured in the presence or absence of 1 μ M
903 thapsigargin for 6 h and *XBPIs* mRNA levels were measured by RT-qPCR. Values of *XBPIs*
904 mRNA were normalized to total *XBPI* mRNA levels for each condition. (\pm SD, n=3),
905 ***p<0.0005.

906

907

908

909

910

911

912

913

914

915

916


917

918

919

920

Supplemental Fig. 5



921

922 **Supplemental Figure 5.** (A) Schematic of IRE1-sgRNAs (1 and 2) and the gene region that was

923 amplified by RT-qPCR to verify loss of *IRE1* expression. (B) Viability assay of DCs at

924 designated hours post-transfection with gRNA-IRE1 (*ire1* (-)) or random gRNA (WT). (C)

925 Infected WT and *ire1* (-) DCs were incubated with cell tracker and then inoculated into mice by

926 i.p. injection using 10^6 infected cells. At the indicated hpi, the spleen of each mouse was

927 harvested and the cell tracker fluorescence was measured using a plate reader. Values of

928 fluorescence were normalized to uninfected (fold change). ** $p < 0.01$ and **** $p < 0.0001$.

929 **Supplementary Table 1 Oligonucleotide primers used in this study.**

Primer	5'—3'
<i>Xbp1-F</i>	ACATCTTCCCATGGACTCTG
<i>Xbp1-R</i>	TAGGTCCTTCTGGGTAGACC
<i>Xbp1u-F</i>	GAAGAGAACCACAAACTCCAGC
<i>Xbp1u-R</i>	GCAGAGGTGCACATAGTCTGAG
<i>Xbp1s-F</i>	GAGTCCGCAGCAGGTG
<i>Xbp1s-R</i>	TCCAGAATGCCCAAAGG
<i>Edem-F</i>	GGGACCAAGAGGAAAAGTTTG
<i>Edem-R</i>	GAGGTGAGCAGGTCAAATCAA
<i>Hrd1-F</i>	AGCTACTTCAGTGAACCCCACT
<i>Hrd1-R</i>	CTCCTCTACAATGCCCACTGAC
<i>Grp78-F</i>	TGTGGTACCCACCAAGAAGTC
<i>Grp78-R</i>	TTCAGCTGTCACTCGGAGAAT
<i>Erdj4-F</i>	CTTAGGTGTGCCAAAGTCTGC
<i>Erdj4-R</i>	GGCATCCGAGAGTGTTCATA
<i>P58ipk-F</i>	GTGGCATCCAGATAATTTCCAG
<i>P58ipk-R</i>	GAGTTCCAACCTTCTGTGGAAGG
<i>Pdia6-F</i>	TGGTTCCTTTCCTACCATCACT
<i>Pdia6-R</i>	ACTTTCCTGCTGGAAAACCTGC
<i>Ero1l-F</i>	CGGACCAAGTTATGAGTTCCA
<i>Ero1l-R</i>	TCAGAGAGATTCTGCCCTTCA
<i>Ire1-wt-F</i>	TCTAGAACCATGCCGGCCCGGCGGCTGCTGCTGCTGCTGAC
<i>Ire1-wt-R</i>	GAGGGCGTCTGGAGTCACTGGGGGCTGGGGCTCTGGGGGCTCG
<i>Ire1-kD-F</i>	GCGACGTGGCCGTGAGGATCCTCCCCGAG
<i>Ire1-kD-R</i>	GGTTGTCAAACATGCCCCGGTACA
<i>Ire1-eD-F</i>	CTCCGAGCCATGAGAGAAGCACCCTACCGGGAGCTGCC

<i>Irel-eD-R</i>	GAGATCTCTGACAGAACCACCTTTAT
<i>Irel-oD-F</i>	GGTAAAAAGCAGATCTGGTATGTTATTGACCT
<i>Irel-oD-R</i>	CATGTAGAGGATTCCATCTGAACTTCGGCATG
<i>Irel-Δ965-F</i>	TGAGCGAGGGCGGCCCC
<i>Irel-Δ965-R</i>	CAGCTCCCGGTAGTGGTGCTTCTTATTTC
<i>Gapdh-F</i>	TCACCACCATGGAGAAGGC
<i>Gapdh-R</i>	GCTAAGCAGTTGGTGGTGCA

930

931

932 **Supplementary Table 2 Reagents used in this study.**

Reagent	Company names
Antibody	
PERK-P	Phospho-PERK (Thr980) (16F8) Rabbit mAb #3179- Cell Signaling
PERK	PERK (C33E10) Rabbit mAb #3192- Cell Signaling
ATF6	[30]
XBP1s	XBP-1s (D2C1F) Rabbit mAb #12782- Cell Signaling
GAPDH	ab9485-Abcam
Phalloidin	R415-Thermo Fisher Scientific
SAG1	Toxoplasma gondii P30 Monoclonal Antibody (P30/3)- Thermo Fisher Scientific
IRE1	ab37073-Abcam
Myc	Myc-Tag (71D10) Rabbit mAb #2278-Cell Signaling
GFP	clone GFP-20-Sigma Aldrich
Filamin A-P (S2152)	Phospho-Filamin A (Ser2152) Antibody #4761-Cell Signaling
Filamin A	Filamin A Antibody #4762-Cell Signaling
Reagent	
Fluo-4, AM	F14201-Thermo Fisher Scientific
Ry	1329-Tocris
XeC	(-)-Xestospongin C- 1280-Tocris
IP ₃	D-myo-Inositol 1,4,5-trisphosphate- 1482-Tocris
caffeine	C53-Sigma Sigma Aldrich
Mag-Fluo-4	M14206- Thermo Fisher Scientific
PERKi	GSK2656157- 5.04651-Sigma Aldrich
4μ8c	4479-Tocris
Ceapin-A7	SML2330-Sigma Aldrich
KIRA6	19151-Cayman Chemical

Collagen I	A1048301-Gibco
Thapsigargin	1138-Tocris
DAPI	D9542-Sigma Aldrich

933